App-Quantinova.ai

The Validity and Reliability of Online Obituaries as a Source of Mortality Data

John Granton - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Pulmonary arterial hypertension

N/A

Poor Agreement between Clinical Swelling and Ultrasound-Detected Synovial Thickening in Metatarsophalangeal Joints of Patients with Early Rheumatoid Arthritis

George Ioannidis - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

High Accuracy and Significant Savings using TaqMan Tag-SNP Genotyping to Determine HLA-B*27 Status in the Newfoundland Population

Josh Lehr - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Acute Anterior Uveitis in Ankylosing Spondylitis: Association with Inflammatory Bowel Di sease and Psoriasis Independent of HLA B27

Tristan Boyd - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Ankylosing spondylitis

N/A

A Systematic Review to Characterize Healthcare Utilization for Indigenous People Living with Arthritis in Canada, New Zealand, Australia and the United States

Kelle Edgar - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

What is the Location of Enthesitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?

Denis Choquette - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Infliximab

Effectiveness and Safety of Golimumab in the Treatment of Rheumatoid Arthritis over a 24 Month Period

John Kelsall - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Infliximab

What Proportion of Patients Fail to Achieve CDAI and SDAI Remission based on Physician Global Assessment? An Analysis from a Prospective, Observational Registry

Boulos Haraoui - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Infliximab

Current Smoking, its Intensity and Duration, is Associated with Fat Metaplasia on MRI in Patients with Spondyloarthritis

Stephanie Wichuk - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Spondyloarthritis

N/A

Minimal Disease Activity among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria are more Prevalent among Responders?

Andrew Chow - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Infliximab

IL-1 Blocker Therapy for Articular Flares in PAPA Syndrome

Jennifer Stimec - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Pyogenic sterile arthritis, pyoderma gangrenosum, and acne syndrome

Interleukin

Use of Social Media by People with Arthritis and Multi-Morbidity: Implications for SelfManagement

Anne Townsend - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Inflammatory Arthritis

N/A

Quality of Life in Patients with Active Non Radiographic Axial Spondyloarthritis After 16 Weeks of Golimumab Treatment

Sean Curtis - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

golimumab

Levels of 14-3-3? Protein Supplement CRP, Age and Antibodies to Predict Progression in Patients with Recent-Onset Inflammatory Polyarthritis

Anthony Marotta - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

A Qualitative Study of Barriers & Facilitators to Arthritis Patient- use of Physical Activity Monitoring Tools

Bao Tran - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Inflammatory Arthritis

N/A

Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Non Radiographic Axial Spondyloarthritis

Gina Bergman - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

golimumab

How Accurate is Spot Urine Protein/Creatinine Ratio in Measuring the Change Over Time in Proteinuria Level Compared to the 24 Hour Proteinuria Test in Lupus Patients?

Murray Urowitz - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Albuminuria

N/A

Diagnostic and Screening Accuracy of Spot Urinary Protein Creatinine Ratio Compared to Protein Content in a 24 Hour-Urine Collection in Systemic Lupus Erythematosus: Systematic Review and Meta-Analysis

Jorge Medina-Rosas - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Patient- Reported Perceived Deficits Questionnaire - 5-Item is Not Valid to Screen for Cognitive Impairment in Lupus

Murray Urowitz - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Depression

N/A

Risk of Chronic Obstructive Pulmonary Disease (COPD) in Rheumatoid Arthritis (RA): A Population Based Study

Antonio Avina-Zubieta - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Filters

28841 Abstracts